Sana Biotechnology Inc at Goldman Sachs Global Healthcare Conference Transcript
Good afternoon. Thanks, everyone, for joining us. We're really pleased to have Sana here with us. And we have Steve Harr, who's President and CEO.Steve, Sana is a preclinical biotechnology company that's focused on cell engineering in a broad sense with a dual platform approach. Could you just give us a brief overview of both your ex vivo hypoimmune and in vivo fusogen technologies? And remind us how your platform is differentiated versus others?
Questions & Answers
Yes. First of all, thank you, Salveen, for having us. It's a beautiful location, and it's always nice to get out and see people again. And I appreciate everybody who's been going at it for a long day for joining us, and we'll try to make sure this is hugely entertaining part of your day and worthwhile, so thank you.
So we will make forward-looking statements just on the -- so everybody, so we do spend time running our risk factors and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
